Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (141-150 of 271) with videos related to

Pageof 28
Sort By:
Cancer|August 24, 2017
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiationFumi Kawakami, Kanishka Sircar, Jaime Rodriguez-Canales, et al.
Current Medical Research and Opinion|August 9, 2014
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United StatesJames E Signorovitch, Nicholas J Vogelzang, Sumanta K Pal, et al.
Cancer Research|April 24, 2014
Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant proteinZhiyong Ding, Peter German, Shanshan Bai, et al.
The Journal of Urology|April 16, 2017
Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy ErasSarp K Keskin, Pavlos Msaouel, Kenneth R Hess, et al.
Expert Opinion on Pharmacotherapy|March 14, 2015
Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United StatesMichael K Wong, Eric Jonasch, Sumanta K Pal, et al.
The Oncologist|August 27, 2015
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II TrialMehmet Asim Bilen, Amado J Zurita, Nasreen A Ilias-Khan, et al.
The Oncologist|March 15, 2019
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)Manuela Schmidinger, Aristotelis Bamias, Giuseppe Procopio, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
The Journal of Urology|December 21, 2010
Metastasectomy after targeted therapy in patients with advanced renal cell carcinomaJose A Karam, Brian I Rini, Leticia Varella, et al.
The Lancet. Oncology|October 22, 2013
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialBrian I Rini, Bohuslav Melichar, Takeshi Ueda, et al.
Pageof 28

Showing results (141-150 of 271) with videos related to

Sort By:
Pageof 28
Cancer|August 24, 2017
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiationFumi Kawakami, Kanishka Sircar, Jaime Rodriguez-Canales, et al.
Current Medical Research and Opinion|August 9, 2014
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United StatesJames E Signorovitch, Nicholas J Vogelzang, Sumanta K Pal, et al.
Cancer Research|April 24, 2014
Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant proteinZhiyong Ding, Peter German, Shanshan Bai, et al.
The Journal of Urology|April 16, 2017
Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy ErasSarp K Keskin, Pavlos Msaouel, Kenneth R Hess, et al.
Expert Opinion on Pharmacotherapy|March 14, 2015
Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United StatesMichael K Wong, Eric Jonasch, Sumanta K Pal, et al.
The Oncologist|August 27, 2015
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II TrialMehmet Asim Bilen, Amado J Zurita, Nasreen A Ilias-Khan, et al.
The Oncologist|March 15, 2019
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)Manuela Schmidinger, Aristotelis Bamias, Giuseppe Procopio, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
The Journal of Urology|December 21, 2010
Metastasectomy after targeted therapy in patients with advanced renal cell carcinomaJose A Karam, Brian I Rini, Leticia Varella, et al.
The Lancet. Oncology|October 22, 2013
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialBrian I Rini, Bohuslav Melichar, Takeshi Ueda, et al.
Pageof 28